Pharma Sector

Is your heartburn pill safe? Panel recommends banning ranitidine in India

An expert panel has recommended suspending ranitidine after tests found cancer-linked NDMA levels in half the samples, bringing India closer to a nationwide ban

Divi's Labs jumps 4% after signing supply agreement with global pharma firm

Divi's Labs stock was quoting at ₹5,855.50, up 3.81 per cent from Thursday, April 17 close of ₹5,640

Hospital valuations keep steady pulse, ensuring growth never skips a beat

Administering the right dose for asset-light expansion and steady margins

Zydus Medtech signs deal with Brazil's Braile Biomedica for TAVI technology

To commercialise transcatheter aortic valve system in India, Europe and other select markets

Indian pharma companies eye larger share of US cancer generics market

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures in the generics space in the US

Results preview: Domestic dose likely to ease US drag for pharma firms

Nuvama Institutional Equities said therapies like antidiabetic, anti-infective and respiratory had underperformed in the Indian pharma market

Stock downfall: The side effects are real, but Sun Pharma stays on its feet

Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain

Russian missile strikes warehouse of Indian pharma firm in Ukraine

A Russian missile struck a warehouse of an Indian pharmaceutical company in Ukraine on Saturday, the Ukrainian embassy in India said. In a social media post, the mission alleged that Moscow is deliberately targeting Indian businesses, destroying medicines meant for children and the elderly. "Today, a Russian missile struck the warehouse of Indian pharmaceutical company Kusum in Ukraine," the Ukrainian embassy said. "While claiming "special friendship" with India, Moscow deliberately targets Indian businesses -? destroying medicines meant for children and the elderly," it posted on X. No further details are immediately available.

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Sensex rejoices on Trump tariff halt, jumps 1,300 pts; Metals, pharma lead

However, on a weekly basis, the Sensex and Nifty posted a decline of 0.27 per cent and 0.33 per cent, respectively

FIIs buy BFSI, telecom, metal stocks in March 2025; should you too?

Banking, financial services, and insurance (BFSI), telecom, and metals saw the highest FII flows in March 2025

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Cipla share price jumps 5% as USFDA okays cancer drug Paclitaxel

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of Leqselvi (deuruxolitinib).

Govt may fast-track food, medicines, farm trade under AEO framework

The AEO programme is implemented by the Central Board of Indirect Taxes and Customs (CBIC) under the aegis of the World Customs Organization's SAFE Framework

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Booster shot as India's pharma market grew 8.4% in FY25: Pharmarack

Augmentin remains top-selling medicine brand at Rs 816 crore sales

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Pharma companies likely to pass on costs in US as fresh levy looms

Brokerages also felt that the pharma companies will aim to pass on the tariff hike to payors

Higher tariffs may significantly dent profits of pharma companies

Companies such as Sun Pharma which have a significant specialty portfolio could be less impacted than Indian peers in the US market given lower competition in niche segments